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Neurodevelopmental disorders, including autism
spectrum disorder (ASD), are defined by core behav-
ioral impairments; however, subsets of individuals
display a spectrum of gastrointestinal (GI) abnormal-
ities. We demonstrate GI barrier defects and micro-
biota alterations in the maternal immune activation
(MIA) mouse model that is known to display features
of ASD. Oral treatment of MIA offspring with the hu-
man commensal Bacteroides fragilis corrects gut
permeability, alters microbial composition, and ame-
liorates defects in communicative, stereotypic, anxi-
ety-like and sensorimotor behaviors. MIA offspring
display an altered serum metabolomic profile, and
B. fragilis modulates levels of several metabolites.
Treating naive mice with a metabolite that is
increased by MIA and restored by B. fragilis causes
certain behavioral abnormalities, suggesting that
gut bacterial effects on the host metabolome impact
behavior. Taken together, these findings support a
gut-microbiome-brain connection in a mouse model
of ASD and identify a potential probiotic therapy for
GI and particular behavioral symptoms in human
neurodevelopmental disorders.INTRODUCTION
Neurodevelopmental disorders are characterized by impaired
brain development and behavioral, cognitive, and/or physical
abnormalities. Several share behavioral abnormalities in socia-
bility, communication, and/or compulsive activity. Most recog-
nized in this regard is autism spectrum disorder (ASD), a serious
neurodevelopmental condition that is diagnosed based on the
presence and severity of stereotypic behavior and deficits in lan-
guage and social interaction. The reported incidence of ASD has
rapidly increased to 1 in 88 births in the United States as of 2008C(Autism and Developmental Disabilities Monitoring Network Sur-
veillance Year 2008 Principal Investigators and CDC, 2012), rep-
resenting a significant medical and social problem. However,
therapies for treating core symptoms of autism are limited.
Much research on ASD has focused on genetic, behavioral,
and neurological aspects of disease, though the contributions
of environmental risk factors (Hallmayer et al., 2011), immune
dysregulation (Onore et al., 2012), and additional peripheral dis-
ruptions (Kohane et al., 2012) in the pathogenesis of ASD have
gained significant attention.
Among several comorbidities in ASD, gastrointestinal (GI)
distress is of particular interest, given its reported prevalence
(Buie et al., 2010; Coury et al., 2012) and correlation with symp-
tom severity (Adams et al., 2011). While the standardized diag-
nosis of GI symptoms in ASD is yet to be clearly defined, clinical
as well as epidemiological studies have reported abnormalities
such as altered GI motility and increased intestinal permeability
(Boukthir et al., 2010; D’Eufemia et al., 1996; de Magistris
et al., 2010). Moreover, a recent multicenter study of over
14,000 ASD individuals reveals a higher prevalence of inflamma-
tory bowel disease (IBD) and other GI disorders in ASD patients
compared to controls (Kohane et al., 2012). GI abnormalities are
also reported in other neurological diseases, including Rett syn-
drome (Motil et al., 2012), cerebral palsy (Campanozzi et al.,
2007), and major depression (Graff et al., 2009). The causes of
these GI problems remain unclear, but one possibility is that
they may be linked to gut bacteria.
Indeed, dysbiosis of the microbiota is implicated in the patho-
genesis of several human disorders, including IBD, obesity, and
cardiovascular disease (Blumberg and Powrie, 2012), and
several studies report altered composition of the intestinal mi-
crobiota in ASD (Adams et al., 2011; Finegold et al., 2010; Fine-
gold et al., 2012; Kang et al., 2013; Parracho et al., 2005;Williams
et al., 2011; Williams et al., 2012). Commensal bacteria affect a
variety of complex behaviors, including social, emotional, and
anxiety-like behaviors, and contribute to brain development
and function in mice (Collins et al., 2012; Cryan and Dinan,
2012) and humans (Tillisch et al., 2013). Long-range interactions
between the gut microbiota and brain underlie the ability of
microbe-based therapies to treat symptoms of multiple sclerosisell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc. 1451
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Figure 1. MIA Offspring Exhibit GI Barrier
Defects and Abnormal Expression of Tight
Junction Components and Cytokines
(A) Intestinal permeability assay, measuring FITC
intensity in serum after oral gavage of FITC-
dextran. Dextran sodium sulfate (DSS): n = 6, S
(saline+vehicle): adult n = 16; adolescent n = 4, P
(poly(I:C)+vehicle): adult n = 17; adolescent n = 4.
Data are normalized to saline controls.
(B) Colon expression of tight junction components
relative to b-actin. Data for each gene are
normalized to saline controls. n = 8/group.
(C) Colon expression of cytokines and inflamma-
tory markers relative to b-actin. Data for each gene
are normalized to saline controls. n = 6–21/group.
(D) Colon protein levels of cytokines and chemo-
kines relative to total protein content. n = 10/group.
For each experiment, data were collected simul-
taneously for poly(I:C)+B. fragilis treatment group
(See Figure 3). See also Figure S1.and depression inmice (Bravo et al., 2011; Ochoa-Repa´raz et al.,
2010), and the reported efficacy of probiotics in treating
emotional symptoms of chronic fatigue syndrome and psycho-
logical distress in humans (Messaoudi et al., 2011; Rao et al.,
2009).
Based on the emerging appreciation of a gut-microbiome-
brain connection, we asked whether modeling some of the
behavioral features of ASD in a mouse model also causes GI
abnormalities. Several mouse models of genetic and/or environ-
mental risk factors are used to study ASD.We utilize thematernal
immune activation (MIA) model, which is based on large epide-
miological studies linking maternal infection to increased autism
risk in the offspring (Atlado´ttir et al., 2010; Gorrindo et al., 2012).
A number of studies link increased ASD risk to familial autoim-
mune disease (Atlado´ttir et al., 2009; Comi et al., 1999) and
elevated levels of inflammatory factors in the maternal blood,
placenta, and amniotic fluid (Abdallah et al., 2013; Brown et al.,
2013; Croen et al., 2008).ModelingMIA inmice by injecting preg-
nant dams with the viral mimic poly(I:C) yields offspring that
exhibit the core communicative, social, and stereotyped impair-
ments relevant to ASD, as well as a common autism neuro-
pathology—a localized deficiency in cerebellar Purkinje cells
(Malkova et al., 2012; Shi et al., 2009). Furthermore, pregnant
monkeys exposed to poly(I:C) yield offspring with symptoms of
ASD (Bauman et al., 2013). Although several environmental
and genetic risk factors for ASD have been investigated in pre-
clinical models, GI abnormalities have not been reported. We
show herein that offspring of MIA mice, which display behavioral
abnormalities, have defects in intestinal integrity and alterations
in the composition of the commensal microbiota that are analo-
gous to features reported in human ASD. To explore the potential
contribution of GI complications to these symptoms, we1452 Cell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc.examine whether treatment with the gut
bacterium Bacteroides fragilis, demon-
strated to correct GI pathology in mouse
models of colitis (Mazmanian et al.,
2008) and to protect against neuroinflam-mation in mouse models of multiple sclerosis (Ochoa-Repa´raz
et al., 2010), impacts ASD-related GI and/or behavioral
abnormalities in MIA offspring. Our study reflects a mechanistic
investigation of how alterations in the commensal microbiota
impact behavioral abnormalities in amousemodel of neurodeve-
lopmental disease. Our findings suggest that targeting the
microbiome may represent an approach for treating subsets of
individuals with behavioral disorders, such as ASD, and comor-
bid GI dysfunction.
RESULTS
Offspring of Immune-Activated Mothers Exhibit GI
Symptoms of Human ASD
Subsets of ASD children are reported to display GI abnormal-
ities, including increased intestinal permeability or ‘‘leaky gut’’
(D’Eufemia et al., 1996; de Magistris et al., 2010; Ibrahim et al.,
2009). We find that adult MIA offspring, which exhibit a number
of behavioral and neuropathological symptoms of ASD (Malkova
et al., 2012), also have a significant deficit in intestinal barrier
integrity, as reflected by increased translocation of FITC-dextran
across the intestinal epithelium, into the circulation (Figure 1A,
left). This MIA-associated increase in intestinal permeability is
similar to that of mice treated with dextran sodium sulfate
(DSS), which induces experimental colitis (Figure 1A, left). Defi-
cits in intestinal integrity are detectable in 3-week-old MIA
offspring (Figure 1A, right), indicating that the abnormality is
established during early life. Consistent with the leaky gut
phenotype, colons from adult MIA offspring contain decreased
gene expression of TJP1, TJP2, OCLN, and CLDN8 and
increased expression of CLDN15 (Figure 1B). Deficient expres-
sion of TJP1 is also observed in small intestines of adult MIA
offspring (Figure S1A available online), demonstrating a wide-
spread defect in intestinal barrier integrity.
Gut permeability is commonly associated with an altered
immune response (Turner, 2009). Accordingly, colons from adult
MIA offspring display increased levels of interleukin-6 (IL-6)
mRNA and protein (Figures 1C and 1D) and decreased levels
of the cytokines/chemokines IL-12p40/p70 and MIP-1a (Fig-
ure 1D). Small intestines from MIA offspring also exhibit altered
cytokine/chemokine profiles (Figure S1C). Changes in intestinal
cytokines are not accompanied by overt GI pathology, as as-
sessed by histological examination of gross epithelial
morphology from hematoxylin- and eosin-stained sections
(data not shown). Overall, we find that adult offspring of im-
mune-activated mothers exhibit increased gut permeability
and abnormal intestinal cytokine profiles.
MIA Offspring Display Dysbiosis of the Gut Microbiota
Abnormalities related to the microbiota have been identified in
ASD individuals, including disrupted community composition
(Adams et al., 2011; Finegold et al., 2010; Finegold et al.,
2012; Parracho et al., 2005; Williams et al., 2011; Williams
et al., 2012), although it is important to note that a well-defined
ASD-associated microbial signature is lacking thus far. To eval-
uate whether MIA induces microbiota alterations, we surveyed
the fecal bacterial population by 16S rRNA gene sequencing
of samples isolated from adult MIA or control offspring. Alpha di-
versity, i.e., species richness and evenness, did not differ signif-
icantly between control and MIA offspring, as measured by
several indices (Figures S2A and S2B). In contrast, unweighted
UniFrac analysis, which measures the degree of phylogenetic
similarity between microbial communities, reveals a strong ef-
fect of MIA on the gut microbiota of adult offspring (Figure 2).
MIA samples cluster distinctly from controls by principal coordi-
nate analysis (PCoA) and differ significantly in composition (Ta-
ble S3, with ANOSIM R = 0.2829, p = 0.0030), indicating robust
differences in the membership of gut bacteria between MIA
offspring and controls (Figure 2A). The effect of MIA on altering
the gut microbiota is further evident when sequences from the
classes Clostridia and Bacteroidia, which account for approxi-
mately 90.1% of total reads, are exclusively examined by
PCoA (R = 0.2331, p = 0.0070; Figure 2B), but not when Clostri-
dia and Bacteroidia sequences are specifically excluded from
PCoA of all other bacterial classes (R = 0.1051, p = 0.0700; Fig-
ure 2C). This indicates that changes in the diversity of Clostridia
and Bacteroidia operational taxonomic units (OTUs) are the pri-
mary drivers of gut microbiota differences between MIA
offspring and controls.
Sixty-seven of the 1,474 OTUs detected across any of the
samples discriminate between treatment groups, including
those assigned to the bacterial families Lachnospiraceae,
Ruminococcaceae, Erysipelotrichaceae, Alcaligenaceae, Por-
phyromonadaceae, Prevotellaceae, Rikenellaceae, and un-
classified Bacteroidales (Figure 2D and Table S1). Of these 67
discriminatory OTUs (relative abundance: 13.3% ± 1.65% con-
trol, 15.93% ± 0.62% MIA), 19 are more abundant in the control
samples and 48 are more abundant in MIA samples. Consistent
with the PCoA results (Figures 2A–2C), the majority of OTUs that
discriminate MIA offspring from controls are assigned to theCclasses Bacteroidia (45/67 OTUs or 67.2%; 12.02% ± 1.62%
control, 13.48% ± 0.75% MIA) and Clostridia (14/67 OTUs or
20.9%; 1.00% ± 0.25% control, 1.58% ± 0.34% MIA). Interest-
ingly, Porphyromonadaceae, Prevotellaceae, unclassified Bac-
teriodales (36/45 discriminatory Bacteroidial OTUs or 80%;
4.46% ± 0.66% control, 11.58% ± 0.86%MIA), and Lachnospir-
iceae (8/14 discriminatory Clostridial OTUs or 57%; 0.28% ±
0.06% control, 1.13% ± 0.26% MIA) were more abundant in
MIA offspring. Conversely,Ruminococcaceae (2 OTUs), Erysipe-
lotrichaceae (2 OTUs), and the beta Proteobacteria family Alca-
ligenaceae (2 OTUs) were more abundant in control offspring
(Figure 2D and Table S1; 0.95% ± 0.31% control, 0.05% ±
0.01%MIA). This suggests that specific Lachnospiraceae, along
with other Bacteroidial species, may play a role inMIA pathogen-
esis, while other taxa may be protective. Importantly, there is
no significant difference in the overall relative abundance of
Clostridia (13.63% ± 2.54% versus 14.44% ± 2.84%; p =
0.8340) and Bacteroidia (76.25% ± 3.22% versus 76.22 %±
3.46%; p = 0.9943) between MIA offspring and controls (Fig-
ure 2E, left), indicating that alterations in the membership of
Clostridial and Bacteroidial OTUs drive major changes in the
gut microbiota between experimental groups.
Overall, we find that MIA leads to dysbiosis of the gut
microbiota, driven primarily by alterations in specific OTUs of
the bacterial classes Clostridia and Bacteroidia. Changes in
OTUs classified as Lachnospiraceae and Ruminococcaceae of
the order Clostridiales parallel select reports of increased Clos-
tridium species in the feces of subjects with ASD (Finegold
et al., 2012). Altogether, modeling MIA in mice induces not only
behavioral and neuropathological features of ASD (Malkova
et al., 2012; Shi et al., 2009) but also microbiome changes as
described in subsets of ASD individuals.
Bacteroides fragilis Improves Gut Barrier Integrity in
MIA Offspring
Gut microbes play an important role in the development, mainte-
nance and repair of the intestinal epithelium (Turner, 2009). To
determine whether targeting the gut microbiota could impact
MIA-associated GI abnormalities, we treated mice with the
human commensal B. fragilis at weaning, and tested for GI
abnormalities at 8 weeks of age. B. fragilis has previously been
shown to ameliorate experimental colitis (Mazmanian et al.,
2008; Round and Mazmanian, 2010). Remarkably, B. fragilis
treatment corrects intestinal permeability in MIA offspring (Fig-
ure 3A). In addition, B. fragilis treatment ameliorates MIA-associ-
ated changes in expression of CLDNs 8 and 15, but not TJP1,
TJP2, orOCLN (Figure 3B). Similar changes are observed in pro-
tein levels of CLDNs 8 and 15 in the colon, with restoration by
B. fragilis treatment (Figures 3C and 3D). No effects of
B. fragilis on tight junction expression are observed in the small
intestine (Figure S1B), consistent with the fact that Bacteroides
species are predominantly found in the colon. Finally, the pres-
ence of GI defects prior to probiotic administration (Figure 1A,
right) suggests that B. fragilis may treat, rather than prevent,
this pathology in MIA offspring.
B. fragilis treatment also restores MIA-associated increases in
colon IL-6mRNA and protein levels (Figures 3E and 3F). Levels of
other cytokines are altered in both colons and small intestines ofell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc. 1453
Figure 2. MIA Offspring Exhibit Dysbiosis of the Intestinal Microbiota
(A) Unweighted UniFrac-based 3D PCoA plot based on all OTUs from feces of adult saline+vehicle (S) and poly(I:C)+vehicle (P) offspring.
(B) Unweighted UniFrac-based 3D PCoA plot based on subsampling of Clostridia and Bacteroidia OTUs (2003 reads per sample).
(C) Unweighted UniFrac-based 3D PCoA plot based on subsampling of OTUs remaining after subtraction of Clostridia and Bacteroidia OTUs (47 reads per
sample).
(D) Relative abundance of unique OTUs of the gut microbiota (bottom, x axis) for individual biological replicates (right, y axis), where red hues denote increasing
relative abundance of a unique OTU.
(E) Mean relative abundance of OTUs classified at the class level for the most (left) and least (right) abundant taxa. n = 10/group. Data were simultaneously
collected and analyzed for poly(I:C)+B. fragilis treatment group (See Figure 4).
See also Figure S2 and Table S1.MIA offspring (Figures 1D and S1C), but these are not affected by
B. fragilis treatment, revealing specificity for IL-6. We further find
that recombinant IL-6 treatment can modulate colon levels
of both CLDN 8 and 15 in vivo and in in vitro colon organ cultures
(data not shown), suggesting that B. fragilis-mediated restora-
tion of colonic IL-6 levels could underlie its effects on gut
permeability. Collectively, these findings demonstrate that
B. fragilis treatment of MIA offspring improves defects in GI1454 Cell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc.barrier integrity and corrects alterations in tight junction and
cytokine expression.
B. fragilis Treatment Restores Specific Microbiota
Changes in MIA Offspring
The finding that B. fragilis ameliorates GI defects in MIA
offspring prompted us to examine its effects on the intestinal
microbiota. No significant differences are observed following
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Figure 3. B. fragilis Treatment Corrects GI Deficits in MIA Offspring
(A) Intestinal permeability assay, measuring FITC intensity in serum after oral gavage of FITC-dextran. Data are normalized to saline controls. Data for DSS,
saline + vehicle (S) and poly(I:C) + vehicle (P) are as in Figure 1. poly(I:C)+B. fragilis (P+BF): n = 9/group.
(B) Colon expression of tight junction components relative to b-actin. Data for each gene are normalized saline controls. Data for S and P are as in Figure 1.
Asterisks directly above bars indicate significance compared to saline control (normalized to 1, as denoted by the black line), whereas asterisks at the top of the
graph denote statistical significance between P and P+BF groups. n = 8/group.
(C) Immunofluorescence staining for claudin 8. Representative images for n = 5.
(D) Colon protein levels of claudin 8 (left) and claudin 15 (right). Representative signals are depicted below. Data are normalized to signal intensity in saline
controls. n = 3/group.
(E) Colon expression of IL-6 relative to b-actin. Data are normalized to saline controls. Data for S and P are as in Figure 1. P+BF: n = 3/group.
(F) Colon protein levels of cytokines and chemokines relative to total protein content. Data are normalized to saline controls. Data for S and P are as in Figure 1. n =
10/group.
See also Figure S1.B. fragilis treatment of MIA offspring by PCoA (ANOSIM
R = 0.0060 p = 0.4470; Table S3), in microbiota richness (PD:
p = 0.2980, Observed Species: p = 0.5440) and evenness
(Gini: p = 0.6110, Simpson Evenness: p = 0.5600; Figures 4A,
S2A and S2B), or in relative abundance at the class level (Fig-
ure S2C). However, evaluation of key OTUs that discriminate
adultMIA offspring fromcontrols reveals thatB. fragilis treatment
significantly alters levels of 35 OTUs (Table S2). Specifically, MIA
offspring treated with B. fragilis display significant restoration in
the relative abundance of 6 out of the 67 OTUs found
to discriminate MIA from control offspring (Figure 4B and
Table S2), which are taxonomically assigned as unclassified
Bacteroidia and Clostridia of the family Lachnospiraceae
(Figure 4B and Table S2). Notably, these alterations occur inCthe absence of persistent colonization of B. fragilis, which
remains undetectable in fecal and cecal samples isolated from
treated MIA offspring (Figures S2D and S2E). Phylogenetic
reconstruction of the OTUs that are altered by MIA and restored
by B. fragilis treatment reveals that the Bacteroidia OTUs cluster
together into a monophyletic group and the Lachnospiraceae
OTUs cluster into two monophyletic groups (Figure 4C). This
result suggests that, although treatment of MIA offspring with
B. fragilis may not lead to persistent colonization, this probiotic
corrects the relative abundance of specific groups of related
microbes of the Lachnospiraceae family as well as unclassified
Bacteriodales. Altogether, we demonstrate that treatment of
MIA offspring with B. fragilis ameliorates particular MIA-associ-
ated alterations in the commensal microbiota.ell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc. 1455
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Figure 4. B. fragilis Treatment Alters the Intestinal Microbiota and Corrects Species-Level Abnormalities in MIA Offspring
(A) Unweighted UniFrac-based 3D PCoA plot based on all OTUs. Data for saline (S) and poly(I:C) (P) are as in Figure 2.
(B) Relative abundance of key OTUs of the family Lachnospiraceae (top) and order Bacteroidales (bottom) that are significantly altered by MIA and restored by
B. fragilis treatment.
(C) Phylogenetic tree based on nearest-neighbor analysis of 16S rRNA gene sequences for key OTUs presented in (B). Red clades indicate OTUs of the family
Lachnospiraceae and green clades indicate OTUs of the order Bacteriodales. Purple taxa indicate OTUs that are significantly elevated in P and corrected by
B. fragilis (BF) treatment. n = 10/group.
See also Figure S2 and Table S2.B. fragilis Treatment Corrects ASD-Related Behavioral
Abnormalities
Studies suggest that GI issues can contribute to the develop-
ment, persistence, and/or severity of symptoms seen in ASD
and related neurodevelopmental disorders (Buie et al., 2010;
Coury et al., 2012). To explore the potential impact of GI dysfunc-
tion on core ASD behavioral abnormalities, we tested whether1456 Cell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc.B. fragilis treatment impacts anxiety-like, sensorimotor, repeti-
tive, communicative, and social behavior in MIA offspring. We
replicated previous findings that adult MIA offspring display
several core behavioral features of ASD (Malkova et al., 2012).
Open field exploration involves mapping an animal’s movement
in an open arena to measure locomotion and anxiety (Bourin
et al., 2007). MIA offspring display decreased entries and time
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Figure 5. B. fragilis Treatment Ameliorates
Autism-Related Behavioral Abnormalities in
MIA Offspring
(A) Anxiety-like and locomotor behavior in the open
field exploration assay. n = 35–75/group.
(B) Sensorimotor gating in the PPI assay. n = 35–75/
group.
(C) Repetitive marble burying assay. n = 16–45/
group.
(D) Ultrasonic vocalizations produced by adult male
mice during social encounter. n = 10/group.
S = saline+vehicle, p = poly(I:C)+vehicle, P+BF =
poly(I:C)+B. fragilis. Data were collected simul-
taneously for poly(I:C)+B. fragilis DPSA and
poly(I:C)+B. thetaiotaomicron treatment groups
(See also Figures S3 and S4).spent in the center of the arena, which is indicative of anxiety-like
behavior (Figure 5A; compare saline [S] to poly(I:C) [P]). The
prepulse inhibition (PPI) task measures the ability of an animal
to inhibit its startle in response to an acoustic tone (‘‘pulse’’)
when it is preceded by a lower-intensity stimulus (‘‘prepulse’’).
Deficiencies in PPI are a measure of impaired sensorimotor
gating and are observed in several neurodevelopmental disor-
ders, including autism (Perry et al., 2007). MIA offspring exhibit
decreased PPI in response to 5 or 15 db prepulses (Figure 5B).
The marble burying test measures the propensity of mice to
engage repetitively in a natural digging behavior that is not
confounded by anxiety (Thomas et al., 2009). MIA offspring
display increased stereotyped marble burying compared to
controls (Figure 5C). Ultrasonic vocalizations are used to mea-
sure communication by mice, wherein calls of varying types
and motifs are produced in different social paradigms (Grimsley
et al., 2011). MIA offspring exhibit deficits in communication, as
indicated by reduced number and duration of ultrasonic vocali-
zations produced in response to a social encounter (Figure 5D).
Finally, the three-chamber social test is used to measure ASD-Cell 155, 1451–1463, Drelated impairments in social interaction
(Silverman et al., 2010). MIA offspring
exhibit deficits in both sociability, or pref-
erence to interact with a novel mouse
over a novel object, and social preference
(social novelty), or preference to interact
with an unfamiliar versus a familiar mouse
(Figures 5E and 5F). Altogether, MIA
offspring demonstrate a number of be-
havioral abnormalities associated with
ASD as well as others such as anxiety
and deficient sensorimotor gating.
Remarkably, oral treatment with
B. fragilis ameliorates many of these be-
haviors. B. fragilis-treated MIA offspring
do not exhibit anxiety-like behavior in the
open field (Figure 5A; compare poly(I:C)
[P] to poly(I:C)+B. fragilis [P+BF]), as
shown by restoration in the number of
center entries and duration of time spent
in the center of the arena. B. fragilis im-proves sensorimotor gating in MIA offspring, as indicated by
increased combined PPI in response to 5 and 15 db prepulses
(Figure 5B), with no significant effect on the intensity of startle
to the acoustic stimulus (data not shown). B. fragilis-treated
mice also exhibit decreased levels of stereotyped marble
burying and restored communicative behavior (Figures 5C and
5D). Interestingly, B. fragilis raises the duration per call by MIA
offspring to levels exceeding those observed in saline controls
(Figure 5D), suggesting that despite normalization of the pro-
pensity to communicate (number of calls), there is a qualitative
difference in the types of calls generated with enrichment of
longer syllables.
Although B. fragilis-treated MIA offspring exhibit improved
communicative, repetitive, anxiety-like, and sensorimotor
behavior, they retain deficits in sociability and social preference
(Figure 5E). Selective amelioration of ASD-related behaviors is
also seen with risperidone treatment of CNTNAP2 knockout
mice, a genetic mouse model for ASD (Pen˜agarikano et al.,
2011), wherein communicative and repetitive, but not social,
behavior is corrected. These data suggest that there may beecember 19, 2013 ª2013 Elsevier Inc. 1457
differences in the circuitry or circuit plasticity governing social
behavior as compared to the other behaviors and that
B. fragilis treatment may modulate specific circuits during
amelioration of at least someASD and possibly other neurodeve-
lopmental behavioral defects.
Interestingly, behavioral improvement in response toB. fragilis
treatment of MIA offspring is not associated with changes in
systemic immunity (Figures S3A–S3D) and is not dependent on
polysaccharide A (PSA), a molecule previously identified to
confer immunomodulatory effects by B. fragilis (Figure S3E)
(Mazmanian et al., 2008; Ochoa-Repa´raz et al., 2010; Round
and Mazmanian, 2010). Furthermore, amelioration of behavior
is not specific to B. fragilis, as similar treatment with Bacteroides
thetaiotaomicron also significantly improves anxiety-like, repeti-
tive, and communicative behavior in MIA offspring (Figure S4).
This is consistent with our finding that B. fragilis treatment
improves behavioral problems in the absence of evident coloni-
zation of B. fragilis in the GI tract (Figures S2D and S2E) and thus
may be functioning through persistent shifts in the composition
of residentmicrobiota (Figure 4). There is, however, some degree
of specificity to bacterial treatment, as administration of Entero-
coccus faecalis has no effect on anxiety-like and repetitive
behavior in MIA offspring (data not shown).
The Serum Metabolome is Modulated by MIA and
B. fragilis Treatment
Metabolomic studies have shown that gut microbial products
are found in many extraintestinal tissues, and molecules derived
from the microbiota may influence metabolic, immunologic, and
behavioral phenotypes in mice and humans (Blumberg and
Powrie, 2012; Nicholson et al., 2012). Given that MIA offspring
display increased gut permeability, tight junction defects, and
dysbiosis, we hypothesized that gut bacteria may affect the
metabolome of mice. We utilized gas chromatography/liquid
chromatography with mass spectrometry (GC/LC-MS)-based
metabolomic profiling to identify MIA-associated changes in
serum metabolites. Three hundred and twenty-two metabolites
were detected in sera from adult mice (Table S5). Interestingly,
MIA leads to statistically significant alterations in 8% of all serum
metabolites detected (Table S4). Furthermore, postnatal
B. fragilis treatment has a significant effect on the serum metab-
olome, altering 34% of all metabolites detected (Table S5 and
Figure S5).
B. fragilis Treatment Corrects Levels of MIA-Induced
Serum Metabolites
Consistent with the notion that increased intestinal permeability
leads to leakage of gut-derived metabolites into the blood-
stream, we hypothesized that B. fragilis-mediated improvement
of intestinal barrier integrity would restore serum levels of certain
metabolites. We therefore focused on serum metabolites that
are significantly altered by MIA treatment and restored to control
levels by B. fragilis treatment. The most dramatically affected
metabolite is 4-ethylphenylsulfate (4EPS), displaying a striking
46-fold increase in serum levels of MIA offspring that is
completely restored by B. fragilis treatment (Figure 6A). This
metabolite is of particular interest because of the reported
production of 4EPS by GI microbes and proposed role for1458 Cell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc.4EPS in communication by mice (Lafaye et al., 2004). Moreover,
we find that compared to conventionally colonized (SPF [specific
pathogen free]) mice, germ-free (GF) mice display nearly
undetectable levels of serum 4EPS, indicating that serum
4EPS is derived from, or modulated by, the commensal micro-
biota (Figure 6B). Interestingly, 4EPS is suggested to be a uremic
toxin, as is p-cresol (4-methylphenol), a chemically related
metabolite reported to be a possible urinary biomarker for autism
(Altieri et al., 2011; Persico and Napolioni, 2013). MIA offspring
also exhibit elevated levels of serum p-cresol, although the
increase does not reach statistical significance (Table S5). The
fact that 4EPS shares close structural similarity to the toxic
sulfated form of p-cresol (4-methylphenylsulfate; 4MPS) is
intriguing as the two metabolites may exhibit functional overlap
(Figure S6A).
In addition to 4EPS, MIA offspring display significantly
increased levels of serum indolepyruvate, a key molecule of
the tryptophanmetabolism pathway, which is restored to control
levels by B. fragilis treatment (Figure 6A). Indolepyruvate is
generated by tryptophan catabolism and, like 4EPS, is believed
to be produced by gut microbes (Smith and Macfarlane, 1997)
(Figure S6B). MIA offspring also exhibit increased levels of serum
serotonin (0.05 < p < 0.10; Tables S3 and S4), reflecting another
alteration in tryptophan metabolism, analogous to the well-
established hyperserotonemia endophenotype of autism. MIA
also leads to altered serum glycolate, imidazole propionate,
and N-acetylserine levels (Figure 6A), which are corrected by
B. fragilis treatment. How changes in these metabolites may
be relevant to ASD or GI dysfunction is currently unknown but
may be an exciting area for future study. These findings demon-
strate that specific metabolites are altered in MIA offspring and
normalized by B. fragilis treatment, with at least two molecules
(4EPS and indolepyruvate) having potential relevance to ASD.
A Serum Metabolite Induces Anxiety-like Behavior
Do small molecules modulated by the commensal microbiota
play a role in behaviors relevant to ASD? To test this hypothesis,
we examined whether increasing serum 4EPS is sufficient to
cause any ASD-related behavioral abnormalities in naive mice.
Mice were treated with 4EPS potassium salt (Figures S7A–
S7C) or vehicle, daily from 3 weeks of age (when MIA offspring
display gut permeability) to 6 weeks of age (when behavior
testing begins). Remarkably, systemic administration of the
single metabolite, 4EPS, to naive wild-type mice is sufficient to
induce anxiety-like behavior similar to that observed in MIA
offspring (Figure 6C). Relative to vehicle-treated controls, mice
exposed to 4EPS travel comparable distances in the open field
but spend less time in the center arena (Figure 6C). Also, in the
PPI test, 4EPS-treated mice exhibit increased intensity of startle
in response to the unconditioned primary stimulus but no sig-
nificant alterations in PPI (Figure 6D), representing anxiety-
associated potentiation of the startle reflex (Bourin et al.,
2007). Interestingly, vehicle-treated controls exhibit symptoms
of anxiety-like behavior compared to untreated saline offspring
(vehicle vs saline in Figure 6C and 5A), reflecting the well-known
effect of chronic stress (daily injection) on raising anxiety levels in
mice. Conversely, there are no significant differences between
4EPS-treated versus saline-treated mice in marble burying or
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Figure 6. B. fragilis Treatment Corrects MIA-Mediated Changes in 4-ethylphenylsulfate, a Microbe-Dependent Metabolite that Induces
Anxiety-like Behavior
(A) Relative quantification of metabolites detected by GC/LC-MS that are significantly altered by MIA and restored by B. fragilis treatment. n = 8/group.
(B) Serum concentrations of 4EPS detected by LC-MS. n = 1, where each represents pooled sera from 3–5 mice.
(C) Anxiety-like and locomotor behavior in the open field exploration assay. n = 10/group.
(D) Potentiated startle reflex in the PPI assay. n = 10/group.
S = saline+vehicle, P = poly(I:C)+vehicle, P+BF = poly(I:C)+B. fragilis, SPF = specific pathogen-free (conventionally-colonized), GF = germ-free, Veh. = vehicle
(saline), 4EPS = 4-ethylphenylsulfate. U.D. = undetectable. See also Figures S5, S6, and S7 and Tables S3 and S4.USV behavior (Figures S7D and S7E), suggesting that elevating
serum 4EPS levels specifically promotes anxiety-like behavior.
While not a core diagnostic criterion, anxiety is a common
comorbidity that may contribute to cardinal ASD symptoms.
Furthermore, it is possible that complex behaviors may be
modulated by combinations of metabolites. In summary, these
data reveal that elevated systemic levels of a metabolite regu-
lated by gut microbes causes anxiety-like behavior, suggesting
that molecular connections between the gut and the brain may
be associated with specific symptoms relevant to ASD and other
neurodevelopmental disorders.
DISCUSSION
We demonstrate that the MIA mouse model displays behavioral
symptoms relevant to ASD and other neurodevelopmental disor-
ders (Malkova et al., 2012; Shi et al., 2009), while also exhibiting
defective GI integrity, dysbiosis of the commensal microbiota,
and alterations in serum metabolites. At least some of these al-
terations are similar to endophenotypes observed in subsets
of ASD individuals. Increased intestinal permeability (Boukthir
et al., 2010; D’Eufemia et al., 1996; de Magistris et al., 2010)
and microbiome alterations (Adams et al., 2011; FinegoldCet al., 2010; Finegold et al., 2012; Kang et al., 2013; Parracho
et al., 2005; Williams et al., 2011; Williams et al., 2012) are re-
ported in several independent studies of ASD; however, these
findings are challenged by some reports of no significant differ-
ences between cases and controls (Gondalia et al., 2012;
Robertson et al., 2008). The reported prevalence of GI abnormal-
ities in ASD also varies considerably across studies, ranging
from 9%–91%. Many such investigations have methodological
limitations, including inappropriate experimental controls, high
sample heterogeneity, small sample size, and selection bias. In
addition, the definition and assessment of GI symptoms can
differ across studies, contributing to variation. While a number
of studies support a role for GI complications in ASD, additional
prospective population-based studies are needed to evaluate
the frequency of GI symptoms in ASD and the interesting
possibility that GI conditions are enriched in particular ASD
subtypes. The role of GI abnormalities and their contribution to
symptoms in other neurodevelopmental disorders warrants
further investigation as well.
We find that treatment with B. fragilis corrects intestinal
permeability defects, as well as altered levels of tight junction
proteins and cytokines in mice displaying GI and neurological
symptoms related to ASD. The ability of B. fragilis to selectivelyell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc. 1459
ameliorate MIA-associated increases in colon IL-6 is interesting
as this cytokine is required for the development of behavioral
deficits in MIA offspring (Smith et al., 2007). Many cytokines
including IL-6 regulate tight junction expression and intestinal
barrier integrity, and further, a variety of enteric microbes are
known to regulate intestinal tight junction and cytokine levels
(Turner, 2009). Our study suggests that B. fragilis is able to
ameliorate leaky gut by directly targeting tight junction expres-
sion, cytokine production, and/or microbiome composition.
Intriguingly, a recent analysis in humans showed that among
the Bacteroidaceae family, only a single phylotype most closely
related to B. fragilis was selectively depleted in ASD children
compared to matched controls, and most dramatically in those
subjects with more severe GI issues (D.-W. Kang and R. Krajmal-
nik-Brown, personal communication). Thus, the correlation
between B. fragilis and improved intestinal health is present in
both mice and humans.
Consistent with the role of GI microbes in regulating intestinal
permeability and metabolic homeostasis (Nicholson et al., 2012;
Wikoff et al., 2009), we show that B. fragilis treatment corrects
MIA-associated changes in specific serum metabolites that
appear to have a gut origin, suggesting B. fragilis may prevent
leakage of harmful molecules from the GI lumen. In a proof-of-
concept test of the this hypothesis, we reveal that the micro-
bially-modulated metabolite 4EPS, which is elevated in the
circulation by MIA and restored by B. fragilis treatment, is suffi-
cient to induce anxiety-like behavior in naive mice. These data
indicate that metabolomic changes contribute to the onset
and/or persistence of autism-related behavioral abnormalities.
Notably, we show that commensal microbes are required for
the production of serum 4EPS in mice. Several species of
Clostridium are believed to be producers of the precursor 4-
ethylphenol (Nicholson et al., 2012), consistent with our findings
that levels of the Lachnospiraceae family of Clostridia and serum
4EPS are elevated in MIA offspring, and both are corrected by
B. fragilis treatment. Moreover, the structural similarity of 4EPS
to the putative ASD biomarker p-cresol, which also derives
from Clostridium species (Persico and Napolioni, 2013), sug-
gests they may be produced through similar biosynthetic
pathways (see Figure S6A). Similarly, the elevation in serum
indolepyruvate observed in MIA offspring, which is also cor-
rected by B. fragilis treatment, is reminiscent of reported in-
creases in indolyl-3-acryloylglycine (IAG) in human ASD (Bull
et al., 2003), which is involved in GI homeostasis and produced
by bacterial metabolism (Keszthelyi et al., 2009). Although not all
autism-like behaviors are affected by 4EPS alone, our results
warrant the examination of indolepyruvate and several other
serum metabolites, perhaps in combination, for their potential
to impact the spectrum of behaviors relevant to neurodevelop-
mental disorders.
Remarkably, B. fragilis treatment ameliorates abnormal
communicative, stereotyped, sensorimotor and anxiety-like
behaviors in MIA offspring, supporting emerging evidence for a
gut-brain link in modulating neurodevelopmental disorders. A
role for commensal bacteria in modulating behavior is supported
by studies revealing differences between GF and SPF mice in
anxiety-like (Diaz Heijtz et al., 2011), nociceptive (Amaral et al.,
2008) and social behavior (Desbonnet et al., 2013). GF mice1460 Cell 155, 1451–1463, December 19, 2013 ª2013 Elsevier Inc.also exhibit widespread microbiota-dependent changes in brain
gene expression, in pathways relevant to synaptic function and
long-term potentiation (Diaz Heijtz et al., 2011). Furthermore,
microbial treatment can ameliorate depressive (Bravo et al.,
2011) and anxiety-like behavior (Bercik et al., 2011) in SPF
mice, and probiotic treatment has been beneficial in treating
psychological distress and chronic fatigue symptoms in humans
(Messaoudi et al., 2011; Rao et al., 2009). The molecular mech-
anisms underlying how the microbiota regulates brain activity
and behavior are unclear but could be mediated by vagus nerve
innervation, immunomodulation and/or metabolic signaling.
Our findings provide a mechanism by which a human
commensal bacterium can improve ASD-related GI deficits
and behavioral abnormalities in mice. Importantly, particular
behavioral and neuropathological symptoms seen in the MIA
model (and in human autism) are not exclusive to ASD. MIA
offspring exhibit additional endophenotypes that resemble
schizophrenia, such as enlarged ventricles, deficient latent
inhibition and deficient parvalbumin-positive interneurons (Li
et al., 2009; Smith et al., 2007), and the behavioral abnormalities
characteristic to human ASD can be individually seen in other
neurological diseases such as schizophrenia, obsessive
compulsive disorder, Angelman syndrome, and Prader-Willi
syndrome. Moreover, other nondiagnostic behaviors relevant
to ASD, including anxiety and impaired PPI, are commonly
reported in several neurological disorders. The phenotypic
overlaps across different disease diagnoses suggest that our
findings on the gut-microbiome-brain connection and microbe-
based treatments for behavior might be broadly applicable to
various disorders. We propose the transformative concept that
autism, and likely other behavioral conditions, are potentially
diseases involving the gut that ultimately impact the immune,
metabolic, and nervous systems, and that microbiome-medi-
ated therapies may be a safe and effective treatment for these
neurodevelopmental disorders.EXPERIMENTAL PROCEDURES
See Supplemental Information for additional details and references.Animals and MIA
Pregnant C57BL/6Nmice (Charles River;Wilmington,MA) were injected i.p. on
E12.5 with saline or 20 mg/kg poly(I:C) according to methods described in
Smith et al. (2007). All animal experiments were approved by the Caltech
IACUC.B. fragilis Treatment
Mice were selected at random for treatment with B. fragilis NCTC 9343 or
vehicle, every other day for 6 days at weaning. 1010 CFU of freshly grown
B. fragilis, or vehicle, in 1.5% sodium bicarbonate was administered in
sugar-free applesauce over standard food pellets. The same procedure was
used for mutant B. fragilis PSA and B. thetaiotaomicron.Intestinal Permeability Assay
Mice were fasted for 4 hr before gavage with 0.6 g/kg 4 kDa FITC-dextran
(Sigma Aldrich). Four hours later, serum samples were read for fluorescence
intensity at 521 nm using an xFluor4 spectrometer (Tecan). Mice were fed
3% dextran sulfate sodium salt (DSS; MP Biomedicals) in drinking water for
7 days to induce colitis.
16S rRNA Gene Sequence Analysis
16S data were processed and its diversity was analyzed using QIIME 1.6
software package (Caporaso et al., 2010b). OTUs were assigned taxonomic
classification using the basic BLAST classifier (Altschul et al., 1990). For
tree-based alpha- and beta diversity analyses, representative sequences
for eachOTUwere aligned using PyNAST (Caporaso et al., 2010a) and a phylo-
genetic tree was constructed based on this alignment using FastTree (Price
et al., 2009). Beta diversity was assessed from unweighted UniFrac, using
the analysis of similarity (ANOSIM; Fierer et al., 2010), permutational multi-
variate analysis of variance (PERMANOVA; Anderson, 2008), permutational
analysis of multivariate dispersions (PERMDISP; Anderson et al., 2006), and
Moran’s I.
Identification of Differences in Specific OTUs
Key OTUs were identified using: (1) Metastats comparison (White et al., 2009)
and (2) Random Forests algorithm, under QIIME (Knights et al., 2011) or
coupled with Boruta feature selection, in the Genboree microbiome toolset
(Riehle et al., 2012), and (3) Galaxy platform-based LDA Effect Size analysis
(LEfSe; Segata et al., 2011). Key OTUs were than aligned using the SINA
aligner (http://www.arb-silva.de/aligner/; Pruesse et al., 2012), compared to
the SILVA reference database release 111 (Quast et al., 2013) using Arb (Lud-
wig et al., 2004) and visualized using FigTree (http://tree.bio.ed.ac.uk/
software/figtree/). Heat maps of key OTUs were generated by extracting their
relative abundance from theOTU table and clustering data by correlation using
Cluster 3.0 (de Hoon et al., 2004). Abundance data were visualized using Java
TreeView (Saldanha, 2004) (Data Set S1).
Behavioral Testing
MIA and control offspring were behaviorally tested as in Hsiao et al. (2012) and
Malkova et al. (2012). Mice were tested beginning at 6 weeks of age for PPI,
open field exploration, marble burying, social interaction, and adult ultrasonic
vocalizations.
4EPS Sufficiency Experiments
Wild-type mice were injected i.p. with saline or 30 mg/kg 4EPS potassium salt
daily from 3 to 6 weeks of age. A dose-response curve was generated by
measuring serum 4EPS levels at various times after i.p. injection of 30 mg/kg
4EPS (Figure S7C). Mice were behaviorally tested as described above from
6 to 9 weeks of age.
Statistical Analysis
Statistical analysis was performed using Prism software (Graphpad). Data are
plotted in the figures as mean ± SEM. Differences between two treatment
groups were assessed using two-tailed, unpaired Student’s t test withWelch’s
correction. Differences among three ormore groupswere assessed using one-
way ANOVA with Bonferroni post hoc test. Two-way repeated-measures
ANOVA with Bonferroni post hoc test was used for analysis of PPI and
CD4+ T cell stimulation data. Two-way ANOVA with contrasts was used for
analysis of the metabolite data. Significant differences are indicated in the
figures by *p < 0.05, **p < 0.01, ***p < 0.001. Notable near-significant differ-
ences (0.5 < p < 0.1) are indicated in the figures. Notable nonsignificant (and
nonnear significant) differences are indicated in the figures by ‘‘n.s.’’
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, five tables, and one data set and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2013.11.024.
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